Cargando…
Early Changes in Circulating FGF19 and Ang-2 Levels as Possible Predictive Biomarkers of Clinical Response to Lenvatinib Therapy in Hepatocellular Carcinoma
Predictive biomarkers of the response of hepatocellular carcinoma (HCC) to Lenvatinib therapy have not yet been clarified. The aim of this study was to identify clinically significant biomarkers of response to Lenvatinib therapy, to target strategies against HCC. Levels of circulating angiogenic fac...
Autores principales: | Chuma, Makoto, Uojima, Haruki, Numata, Kazushi, Hidaka, Hisashi, Toyoda, Hidenori, Hiraoka, Atsushi, Tada, Toshifumi, Hirose, Shunji, Atsukawa, Masanori, Itokawa, Norio, Arai, Taeang, Kako, Makoto, Nakazawa, Takahide, Wada, Naohisa, Iwasaki, Shuitirou, Miura, Yuki, Hishiki, Satoshi, Nishigori, Shuhei, Morimoto, Manabu, Hattori, Nobuhiro, Ogushi, Katsuaki, Nozaki, Akito, Fukuda, Hiroyuki, Kagawa, Tatehiro, Michitaka, Kojiro, Kumada, Takashi, Maeda, Shin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7073176/ https://www.ncbi.nlm.nih.gov/pubmed/31991869 http://dx.doi.org/10.3390/cancers12020293 |
Ejemplares similares
-
Safety and Efficacy of Lenvatinib Treatment in Child–Pugh A and B Patients with Unresectable Hepatocellular Carcinoma in Clinical Practice: A Multicenter Analysis
por: Ogushi, Katsuaki, et al.
Publicado: (2020) -
Influence of NOS3 rs2070744 genotypes on hepatocellular carcinoma patients treated with lenvatinib
por: Azuma, Shintaro, et al.
Publicado: (2020) -
Author Correction: Influence of NOS3 rs2070744 genotypes on hepatocellular carcinoma patients treated with lenvatinib
por: Azuma, Shintaro, et al.
Publicado: (2021) -
Comparative study between sorafenib and lenvatinib as the first‐line therapy in the sequential treatment of unresectable hepatocellular carcinoma in a real‐world setting
por: Fukushima, Taito, et al.
Publicado: (2021) -
The change rate in serum nitric oxide may affect lenvatinib therapy in hepatocellular carcinoma
por: Kawamura, Atsushi, et al.
Publicado: (2022)